See more : LGI Homes, Inc. (0JSI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Tiziana Life Sciences Ltd (TLSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tiziana Life Sciences Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Sidomulyo Selaras Tbk (SDMU.JK) Income Statement Analysis – Financial Results
- Audioboom Group plc (BOOM.L) Income Statement Analysis – Financial Results
- A.S. Création Tapeten AG (ACWN.DE) Income Statement Analysis – Financial Results
- Cellular Goods PLC (CBX.L) Income Statement Analysis – Financial Results
- Quantum Thinking Limited (8050.HK) Income Statement Analysis – Financial Results
Tiziana Life Sciences Ltd (TLSA)
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 56.00K | 92.00K | 64.00K | 405.00K | 116.00K | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 20.00K | 24.00K | 209.00K | 40.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 45.00K | 72.00K | 40.00K | 196.00K | 76.00K | 54.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 0.00% | 80.36% | 78.26% | 62.50% | 48.40% | 65.52% | 54.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.11M | 12.96M | 13.21M | 5.99M | 2.91M | 4.34M | 4.67M | 2.96M | 6.29M | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 80.00K | 412.00K | 737.00K | 826.00K | 745.00K | 457.00K | 326.00K | 580.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 9.87M | 1.63M | 13.31M | 8.82M | 4.86M | 3.48M | 3.57M | 4.33M | 2.33M | 1.97M | 0.00 | 0.00 | 82.00K | -3.03M | -9.00K | -2.00K | 63.00K | 0.00 | 1.50M | 1.06M | 218.00K | 451.00K | 2.42M | 2.43M | 488.00K | 199.00K |
| Operating Expenses | 17.98M | 14.59M | 27.37M | 30.04M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 790.00K | 1.59M | 2.33M | 2.50M | 2.24M | 1.52M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Cost & Expenses | 17.98M | 14.59M | 27.37M | 28.03M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 801.00K | 1.61M | 2.35M | 2.71M | 2.28M | 1.57M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Interest Income | 1.15M | 0.00 | 0.00 | 8.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 56.00K | 36.00K | 47.00K | 47.00K | 10.00K | 22.00K | 79.00K | 157.00K | 8.00K | 1.00K |
| Interest Expense | 10.00K | 7.00K | 176.00K | 320.00K | 73.00K | 9.46K | 9.00K | 9.00K | 18.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 3.00K | 5.00K | 8.00K | 10.00K | 5.00K | 8.00K | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 96.00K | 51.00K | 141.00K | 89.76K | 198.00K | 12.61K | 11.00K | 8.00K | 0.00 | -794.00K | 3.00K | -195.00K | -489.00K | 0.00 | 238.00K | 300.00K | 59.00K | 133.00K | 33.00K | 20.00K | 32.00K | 21.00K | 20.00K | 25.00K | 1.00K | 1.00K |
| EBITDA | -17.14M | -15.34M | -26.34M | -27.93M | -7.58M | -7.81M | -8.24M | -7.28M | -8.61M | -3.56M | -283.00K | -653.00K | -778.00K | -3.03M | -516.00K | -1.24M | -2.49M | -2.15M | -2.18M | -1.48M | -1.95M | -2.35M | -2.39M | -2.33M | -553.00K | -271.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 948.78% | 0.00% | -921.43% | -1,348.91% | -3,890.63% | -531.60% | -1,879.31% | -1,491.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.98M | -14.59M | -27.37M | -28.03M | -7.77M | -7.82M | -8.25M | -7.29M | -8.61M | -2.76M | -286.00K | -458.00K | -289.00K | -3.03M | -754.00K | -1.54M | -2.55M | -2.29M | -2.21M | -1.50M | -1.98M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,533.33% | 0.00% | 352.44% | 0.00% | -1,346.43% | -1,675.00% | -3,982.81% | -564.44% | -1,907.76% | -1,512.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 742.00K | -811.00K | 717.00K | -312.00K | -73.00K | -8.67K | -9.00K | -9.00K | -18.00K | -808.00K | 3.00K | -195.00K | 0.00 | 0.00 | -4.00K | 31.00K | -37.00K | -8.00K | -10.00K | -5.00K | -8.00K | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -17.24M | -15.40M | -26.66M | -28.34M | -7.85M | -7.83M | -8.26M | -7.30M | -8.63M | -3.57M | -283.00K | -653.00K | -289.00K | 0.00 | -758.00K | -1.51M | -2.59M | -2.29M | -2.22M | -1.50M | -1.99M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 352.44% | 0.00% | -1,353.57% | -1,641.30% | -4,040.63% | -566.42% | -1,916.38% | -1,517.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 449.00K | 0.00 | -3.24M | -2.21M | -540.00K | -1.53M | -1.49M | -89.00K | 0.00 | -60.00K | -3.00K | 195.00K | 489.00K | 3.03M | -28.00K | -81.00K | -169.00K | -118.00K | -82.00K | -114.00K | -30.00K | -65.00K | -89.00K | -83.00K | 0.00 | 0.00 |
| Net Income | -17.69M | -15.40M | -23.42M | -26.13M | -7.31M | -6.30M | -6.77M | -7.21M | -8.63M | -3.51M | -280.00K | -848.00K | -778.00K | -3.03M | -730.00K | -1.43M | -2.42M | -2.18M | -2.14M | -1.39M | -1.96M | -2.31M | -2.33M | -2.27M | -554.00K | -272.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,333.33% | 0.00% | 948.78% | 0.00% | -1,303.57% | -1,553.26% | -3,776.56% | -537.28% | -1,845.69% | -1,402.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| EPS Diluted | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
| Weighted Avg Shares Out (Dil) | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
Tiziana Life Sciences' chief advisor to receive "Giants of MS" award
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2024, during the Consortium of Multiple Sclerosis Centers...
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of...
Tiziana eyes orphan drug designation for multiple sclerosis treatment
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has requested its multiple sclerosis treatment be granted orphan drug designation by the Food and Drug Administration (FDA). Tiziana's intranasal foralumab would be the first to receive the designation for non-active secondary progressive multiple sclerosis were it...
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to...
Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new neuroimaging data which shows its investigational drug intranasal foralumab improved White Matter Z-scores in patients with non-secondary progressive Multiple Sclerosis (na-SPMS). White Matter Z-scores are a statistical measure in neuroimaging studies...
Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new neuroimaging data which shows its investigational drug intranasal foralumab improved White Matter Z-scores in patients with non-secondary progressive Multiple Sclerosis (na-SPMS). White Matter Z-scores are a statistical measure in neuroimaging studies...
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing...
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access Program. The company said it will expand the...
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access Program. The company said it will expand the...
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration...
Source: https://incomestatements.info
Category: Stock Reports